Research and Markets (http://www.researchandmarkets.com/research/q4lwgf/friedreich_ataxia) has announced the addition of the "Friedreich Ataxia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Friedreich Ataxia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Friedreich Ataxia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Report Coverage
- Friedreich Ataxia Overview
- Therapeutics Development
- Pipeline Products for Friedreich Ataxia - Overview
- Pipeline Products for Friedreich Ataxia - Comparative Analysis
- Friedreich Ataxia - Therapeutics under Development by Companies
- Friedreich Ataxia - Therapeutics under Investigation by Universities/Institutes
- Friedreich Ataxia - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Friedreich Ataxia - Products under Development by Companies
- Friedreich Ataxia - Products under Investigation by Universities/Institutes
- Friedreich Ataxia - Companies Involved in Therapeutics Development
- AAVLife
- Bioblast Pharma Ltd.
- BioMarin Pharmaceutical Inc.
- Biovista Inc.
- Catabasis Pharmaceuticals, Inc.
- Edison Pharmaceuticals, Inc.
- Horizon Pharma Plc
- MI.TO. Technology S.r.L.
- Reata Pharmaceuticals, Inc.
- Retrotope, Inc
- Shire Plc
- STATegics, Inc.
- Varinel, Inc.
For more information visit http://www.researchandmarkets.com/research/q4lwgf/friedreich_ataxia
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006065/en/